StockData
Cadrenal Therapeutics, Inc. logo

Cadrenal Therapeutics, Inc. (CVKD) stock

CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/30
$1.72−0.16 (-8.51%)

Close on Nov 18, 2026Market cap $6.14MP/E –Yield 959.30%

Cadrenal Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Cadrenal Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$11.65M. For fiscal 2025 it was -$13.46M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$13.46M–
FY2024Dec 31, 2024-$10.96M–
FY2023Dec 31, 2023-$7.63M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.34M–
Q1 FY2026Mar 31, 2026-$2.51M–
Q4 FY2025Dec 31, 2025-$3.07M–
Q3 FY2025Sep 30, 2025-$2.73M–
Q2 FY2025Jun 30, 2025-$3.73M–
Q1 FY2025Mar 31, 2025-$3.93M–
Q4 FY2024Dec 31, 2024-$4.28M–
Q3 FY2024Sep 30, 2024-$2.46M–
Q2 FY2024Jun 30, 2024-$2.47M–
Q1 FY2024Mar 31, 2024-$1.76M–
Q4 FY2023Dec 31, 2023-$1.26M–
Q1 FY2023Mar 31, 2023-$4.20M–

More Cadrenal Therapeutics figures

See a number that looks wrong?